This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 1994 May 14;343(8907):1172-4.

doi: 10.1016/s0140-6736(94)92394-9.

Minimal residual disease as the target for immunotherapy of cancer

G J Nossal¹

Affiliations

PMID: 7909862
DOI: 10.1016/s0140-6736(94)92394-9

Comment

Minimal residual disease as the target for immunotherapy of cancer

G J Nossal. Lancet. 1994.

. 1994 May 14;343(8907):1172-4.

doi: 10.1016/s0140-6736(94)92394-9.

Author

G J Nossal¹

Affiliation

¹ Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.

PMID: 7909862
DOI: 10.1016/s0140-6736(94)92394-9

No abstract available

PubMed Disclaimer

Comment on

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group.
Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, et al. Riethmüller G, et al. Lancet. 1994 May 14;343(8907):1177-83. doi: 10.1016/s0140-6736(94)92398-1. Lancet. 1994. PMID: 7909866 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information